2016
DOI: 10.1136/bcr-2015-212787
|View full text |Cite
|
Sign up to set email alerts
|

A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face

Abstract: Limited cutaneous scleroderma is a subtype of scleroderma limited to the skin of the face, hands, feet and forearms. We present a case of a 45-year-old woman affected by limited cutaneous systemic scleroderma involving the orofacial region and causing restricted mouth opening. The patient showed noteworthy improvement of the skin lesion by use of a combination of intralesional corticosteroid with hyaluronidase and various multiantioxidants, resulting in amelioration of her mouth opening problem. The patient ga… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 23 publications
0
11
0
Order By: Relevance
“…One case report describes it to be mildly efficacious in treating radiation-induced morphea 7 . However, there are several reports on the use of hyaluronidase injections in another sclerosing disorder, SSc, also known as scleroderma 2, 8, 9. Hyaluronidase injections have been used to successfully treat decreased oral aperture, or microstomia, in the context of perioral involvement of SSc 2, 8.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…One case report describes it to be mildly efficacious in treating radiation-induced morphea 7 . However, there are several reports on the use of hyaluronidase injections in another sclerosing disorder, SSc, also known as scleroderma 2, 8, 9. Hyaluronidase injections have been used to successfully treat decreased oral aperture, or microstomia, in the context of perioral involvement of SSc 2, 8.…”
Section: Discussionmentioning
confidence: 99%
“…However, there are several reports on the use of hyaluronidase injections in another sclerosing disorder, SSc, also known as scleroderma 2, 8, 9. Hyaluronidase injections have been used to successfully treat decreased oral aperture, or microstomia, in the context of perioral involvement of SSc 2, 8. Notably, Melvin et al 2 described hyaluronidase injections for a 53-year-old woman with limited cutaneous SSc and disabling microstomia despite treatment with mycophenolate mofetil and systemic corticosteroids.…”
Section: Discussionmentioning
confidence: 99%
“…40 The patient's sclerotic bands resolved almost completely and the patient could open her mouth more widely. 40 Scleredema Scleredema is a rare disorder of connective tissue, characterized by mucin deposition with skin induration. 41 It has been reported to occur after streptococcal infection 42 and in diabetic patients (scleredema diabeticorum).…”
Section: Sclerodermamentioning
confidence: 95%
“…[36][37][38][39] Abbas and colleagues 40 demonstrated the efficacy of hyaluronidase (four injections, 150IU) in improving sclerosis. 40 Their patient suffered from microstomia of the mouth resulting in tongue atrophy and decreased mouth-opening. 40 The patient's sclerotic bands resolved almost completely and the patient could open her mouth more widely.…”
Section: Sclerodermamentioning
confidence: 99%
See 1 more Smart Citation